A rapid precurarization technique using rocuronium.
OBJECTIVE
To evaluate a rapid and time-saving precurarization technique using rocuronium to prevent succinylcholine-induced myalgia.


METHODS
In a prospective, double blind randomized study, 42 ASA 1-2 patients were assigned to one of three pretreatment groups: 0.01 ml.kg-1 normal saline, 0.1 mg.kg-1 atracurium, and 0.1 mg.kg-1 rocuronium. Anaesthesia commenced with 1.5 micrograms.kg-1 fentanyl and 0.5 mg.kg-1 lidocaine at time zero. Pretreatment was administered 60 sec later, followed by 2.5 mg.kg-1 propofol. At 90 sec, 1.5 mg.kg-1 succinylcholine was injected and 30 sec later, the trachea was intubated and the ease of intubation was graded. The patient was observed for the presence and severity of fasciculations. Myalgias were recorded on postoperative days 1, 2 and 7.


RESULTS
The incidence of fasciculations in the rocuronium group (21.4%) was lower (P < 0.001) than atracurium (78.5%) or placebo (92.8%) groups. On postoperative day 1, the incidence of postoperative myalgia in the rocuronium group (14.2%) was less than the placebo group (78.2%; P < 0.002) and atracurium group (85.7%; P < 0.001). The incidence of myalgia in the rocuronium group (7.1%) was lower than in the placebo group (78.5%; P < 0.001) but not different from the atracurium group (42.8%; P = 0.077) on postoperative day 2. On postoperative day 7, there was no difference among the three groups. Fasciculations were related to postoperative myalgia. There was no difference in intubating conditions among the three groups.


CONCLUSIONS
Rocuronium pretreatment given just before induction of anaesthesia with propofol reduces fasciculations and succinylcholine-induced myalgia.
Tsui
B C
BC
Department of Anaesthesia, University of Alberta Hospital, Edmonton, Alberta, Canada.
Reid
S
S
Gupta
S
S
Kearney
R
R
Mayson
T
T
Finucane
B
B
D000328:Adult; D000732:Androstanols / Q000494:pharmacology*; D004311:Double-Blind Method; D005207:Fasciculation / Q000517:prevention & control*; D006801:Humans; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000494:pharmacology*; D010146:Pain / Q000517:prevention & control*; D011446:Prospective Studies; D000077123:Rocuronium; D013390:Succinylcholine / Q000009:adverse effects*
D000732:Androstanols; D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents; D013390:Succinylcholine; D000077123:Rocuronium